For the fourth quarter of FY 2021–22, Glenmark's consolidated revenue was at Rs. 30,191 million as against Rs. 28,599 million recording an increase of 5.6 % YoY.

Adjusted EBITDA was Rs. 5,022 million in the quarter ended March 31, 2022, with margins of 16.6 %.

Reported EBITDA was Rs. 4,634 million in the quarter ended March 31, 2022, as compared to Rs. 5,234 million in the previous corresponding quarter with margins of 15.3%.

Adjusted Net Profit (PAT) was at Rs. 2,939 million for the quarter ended March 31, 2022.

Reported PAT was at Rs. 1,726 million for the quarter ended March 31, 2022, as compared to Rs. 2,340 million in the previous corresponding quarter.

For the year ended March 31, 2022, Glenmark's consolidated revenue was at Rs. 1,23,049 million as against Rs. 1,09,439 million recording an increase of 12.4 % over the previous corresponding period.

Adjusted EBITDA for the fiscal year ended March 31, 2022, stood at Rs. 23,591 million.

Reported EBITDA for the fiscal year ended March 31, 2022 stood at Rs. 23,203 as against Rs. 20,844 million in the previous corresponding period. Net Profit (PAT) was at Rs. 9,936 million for the year ended March 31, 2022, as against Rs. 9,701 million. in the previous year. Earnings Per Share (EPS) is at Rs. 33.4 as compared to Rs. 34.4 YoY basis.

"We delivered consistent performance throughout the year and achieved our key objectives, despite challenging global macro environment. We were able to successfully list Glenmark Lifesciences on the Indian bourses. The out-licensing deal for ISB 880 with Almirall and US FDA approval for Ryaltris, further established us as the leading innovation-driven pharma company in the country." said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. He added,"We are confident of growing our business with continuous emphasis on innovation, sustainability, and prioritizing free cash generation for additional debt reduction."